Azimutus is a leading independent advisory firm specializing in M&A transaction advisory and growth capital.
We help our clients realize their strategic goals and create value through M&A transactions. We work for leading local companies, multinational corporations and private equity funds.
Azimutus was established in 2004 and since then has delivered over 150 projects. We support our clients in buy-side and sell-side processes, as well as in the area of related strategic advisory. We are able to undertake complex assignments.
We successfully execute projects in Europe, having access to both global industry and financial investors, as well as attractive acquisition targets.
Azimutus Biotech & Healthcare. Based in Oxford and with strong links with the Oxford-Cambridge-London golden triangle, our senior specialist team has extensive Biotech, Healthcare and Big Pharma experience and close ties to the European and US venture capital ecosystem.
Azimutus investment banking team is led by:
Witold has 24 years of experience encompassing corporate finance, M&A, venture capital and high technology start-ups. Since founding Azimutus in 2004, he has led over 100 advisory projects for entrepreneurs, multinationals and private equity funds across several industries, including FMCG, food and agri, as well as manufacturing.
Before founding Azimutus, Witold worked at McKinsey & Company. Prior to that, he spent the first seven years of his career in Silicon Valley in California, working for Celera Corporation and Theravance Biopharma.
Witold graduated at the top of his class with an MBA from IESE Business School in Barcelona with part of the studies completed at Columbia Business School in New York. He also has obtained a graduate degree in biomedicinal chemistry from University of California at Berkeley. He obtained his undergraduate degree from Boston University. He is a co-author of 10 scientific publications and patents.
Bilingual in English and Polish, Witold also speaks Spanish.
He is married with two children. His interests include history, literature and astrophysics. Witold is also an ironman triathlete and currently competes in Masters track & field events.
LENNARD VAN SOEST
Lennard has over 25 years of B2B leadership experience in the areas of business development, sales & marketing, business analysis and engineering in global multinationals, scale-up businesses and start-ups in a variety of industries: Medical Devices, Healthcare products, Energy Engineering Services, Regtech and Healthtech. Having worked and lived on four continents Lennard brings a wealth of mature and high growth market experience.
Prior to joining Azimutus, Lennard worked at Ansell Healthcare, Schlumberger Oilfield Services and Noble Drilling. Lennard is cofounder of PolyCat Partners and continues to work with Corus, a European Dentaltech Scale-up. Lennard has a MSc in Petroleum Engineering from Delft University of Technology and a MBA from IESE Business School in Barcelona. He speaks Dutch, English, Spanish and French
Based in Brussels, Belgium, he is married and has two children. Lennard enjoys hiking, mountain- and trail-running.
Senior Advisor Biotech
Paul Brennan received his PhD in organic chemistry from the University of California, Berkeley under the mentorship of Paul Bartlett working on synthetic methodology for combinatorial chemistry and synthesizing inhibitors for new anti-bacterial targets. Following three years of post-doctoral research with Steve Ley in Cambridge University on the total synthesis of rapamycin, Paul returned to California to take a position at Amgen. His research was focussed on designing and synthesizing kinase inhibitors for oncology. After two years at Amgen, Paul accepted a position as medicinal chemistry design lead at Pfizer in Sandwich, UK.
Over the next six years Paul designed and synthesized compounds for most major drug classes: kinases, GPCR’s, CNS-targets, ion-channels and metabolic enzymes. In 2011 Paul joined the Structural Genomics Consortium as a principal investigator to discover chemical probes for epigenetic proteins. He is currently a Professor of Medicinal Chemistry and head of chemistry of the Alzheimer’s Research UK Oxford Drug Discovery Institute in the Centre for Medicines Discovery at the University of Oxford. His research is focused on finding new treatments for dementia and discovering chemical probes for novel protein families.